a henry stewart talks series in biomedicine and the life ... documents/apoptosis brochure for...

State of the art briefings at your computer, whenyou want them, as often

as you want them.

The Speakers:

Dr. Eric Baehrecke

Dr. Simone Fulda

Dr. Irene Ghobrial

Prof. Douglas Green

Prof. MichaelHengartner

Prof. Peter Henson

Prof. Martin Herrmann

Dr. David Huang

Prof. Marja Jäättelä

Prof. Richard Kolesnick

Prof. Peter Krammer

Prof. Yuri Lazebnik

Prof. Jean-ClaudeMartinou

Prof. Gerry Melino

Prof. Shigekazu Nagata

Prof. Pierluigi Nicotera

Dr. Tom O’Brien

Prof. Moshe Oren

Prof. Kodi Ravichandran

Prof. Guy Salvesen

Prof. Yigong Shi

Dr. Richard Siegel

Prof. Herman Steller

Dr. Henning Walczak

n Talks specially commissioned for this series

n Simple format – animated slides withaccompanying narration, synchronized foreasy listening

n Look and feel of face-to-face seminars thatpreserve each speaker’s personality andapproach

n For research scientists, graduate students andthe most committed senior undergraduates

n Available online and on CD-ROM with licensingoptions to meet everyone’s needs

A Henry Stewart Talks Series in Biomedicine and the Life Sciences

To order online and view extracts from the series, please visit www.hstalks.com/apoptosis/

ApoptosisFundamentals, Pathways, ClinicalApplications and Role in Disease

Target Audience:Biochemists, Cell Biologists, Developmental Biologists, Neurobiologists,Immunologists and all researchers involved in developing the clinicalapplications of apoptosis research

Topics covered

ApoptosisFundamentals, Pathways, ClinicalApplications and Role in Disease

24 seminar style presentations by manyof the world’s leading authorities

l The apoptotic pathwayl Mechanisms of apoptosisl Apoptotic cellsl The Bcl-2 family

l Caspasesl The p53 familyl Apoptosis and diseasel Clinical applications

Series Editor:Prof. Michael Hengartner, Ernst Hadorn Professor of Molecular Biology,Institute of Molecular Biology, University of Zurich, Switzerland

This is definitely a ‘must have’ resource to which every researcher should have access. Dr. Hengartnerhas done a masterful job of organizing a coherent and stimulating overview of the apoptosis field.

Prof. John Reed, President and Chief Executive Officer, The Burnham Institute, USA

Evolution of the Apoptotic Pathway

1. Apoptosis in C. elegansProf. Michael Hengartner – Institute of Molecular Biology, University of Zurich,SwitzerlandProgrammed cell death in C. elegans during development and adulthood –Differentiation – The genetic pathway for programmed cell death – Ced-3, Ced-4 and Ced-9 – Activation of the cell death machinery during C. elegansdevelopment and in C. elegans vs. mammals – How does C. elegans regulateactivation of the apoptosome? – Cell death specification (ces) genes – NSM sistercell death – Transcription factors – A model for C. elegans DNA damageresponse – Gla-3 – A molecular model for the recognition and removal ofapoptotic cells in C. elegans

2. Regulation of Apoptosis: Lessons fromDrosophila and their Implications for HumanHealth and DiseaseProf. Herman Steller – Howard Hughes Medical Institute, The RockefellerUniversity, USAMany different signals influence apoptosis – “Gas” and “brake” model ofapoptosis – Reaper, hid and grim – IAPs and cancer – Use of Drosophila –Ubiquitination and apoptosis – diap1 – In proliferating tissues, damage-inducedcell death is compensated by extra growth of the neighboring cells – Evidence forthe “active model” of compensatory proliferation – Regulation of caspaseactivation – Cytochrome c is required for effector caspase activation inDrosophila spermatids – Cyt-c-d and other apoptosome proteins are required fornormal developmental apoptosis in the Drosophila retina – Generation of Sept4-null mice – Acquired characteristics of cancer cells

3. Apoptotic Pathways in MammalsProf. Douglas Green – St. Jude Children’s Research Hospital, USAApoptosis and programmed cell death – Apoptosis: developmental signals,damage or stress, loss of adhesion and oncogenesis – Caspases: inactive andactive – Death folds – Inhibitors of apoptosis proteins – Death receptor (extrinsic)pathway – Mitochondrial (intrinsic) pathway – The Bcl-2 family proteins –Activation, repression and de-repression – Caspase-independent cell death –Cells die in the absence of caspase activation

The Apoptotic Pathway in Humans

4. The Death Receptor Signaling PathwayDr. Richard Siegel – NIAMS, National Institutes of Health, USADeath receptors and ligands – Structural features – Receptor signaling complexes– Regulation of death receptor signaling – Receptor oligomerization andinternalization – Genetic diseases affecting death receptors – Manipulating deathreceptors with therapeutics

5. Mitochondria in ApoptosisProf. Jean-Claude Martinou – University of Geneva, SwitzerlandCell death – Mitochondria – Mitochondrial membrane permeabilization – Bcl-2 –Bax – Permeability transition pore – Cytochrome c – Mechanistic explanations –Cancer – Degenerative diseases

Apoptosis Molecules

6. The Bcl-2 FamilyDr. David Huang – Walter and Eliza Hall Institute of Medical Research, AustraliaApoptosis – Discovery of Bcl-2 – Cell death in worms – Evolutionarily conservedpathways to cell death – How cell death initiates – BH3-only proteins – Control of

BH3-only proteins – Promiscuous and selective BH3-only proteins – Diverse Bcl-2pro-survival proteins must be neutralized for apoptosis – Pro-survival Bcl-2proteins restrain Bax and Bak – Apoptosis in the absence of “activator” BH3-onlyproteins – BH3-only proteins activate Bax and Bak indirectly – Control of Bak –Outstanding questions

7. CaspasesProf. Yuri Lazebnik – Cold Spring Harbor Laboratory, USAWhat makes apoptotic cells alike? – What are caspases? – From the worm tohumans – What is special about proteases? – What do blood clotting and apoptosishave in common? – How do caspases disassemble a cell? – How do you find out ifcaspases are active? – How are caspases activated? – What is left to learn?

8. Natural Caspase InhibitorsProf. Guy Salvesen – The Burnham Institute for Medical Research, USAProteolytic mechanisms – Caspases – Activation mechanisms – Natural caspaseinhibitors – Viral inhibitors – IAPs – Inhibitory mechanisms – IAP antagonists –Theory of activating apoptosis by de-repression of caspase inhibition

9. Mechanisms of Apoptosis from Structural BiologyProf. Yigong Shi – Princeton University, USAStructural mechanism of IAP recognition by Smac/DIABLO – Structuralmechanism of caspase-9 inhibition by XIAP-BIR3 – Structural mechanism ofeffector caspase inhibition by XIAP – Structural mechanism of initiator caspaseactivation – Structural biology of the apoptosome – Structural biology of theprogrammed cell death pathway in C. elegans

10. TRAIL-Induced Apoptosis: From Analysisof the Death-Inducing Signaling Complexto Clinical ApplicabilityDr. Henning Walczak – German Cancer Research Center, GermanyApoptosis induction by the TNF-related apoptosis-inducing ligand (TRAIL) –Apoptosis-inducing TNF super-family ligands and receptors – Formation of thedeath-inducing signaling complex (DISC) – Caspase-8 vs. caspase-10 – Synergyof TRAIL with chemotherapeutics – Tumour specificity of TRAIL-induced apoptosis– Regulation of sensitivity vs. resistance towards TRAIL-induced apoptosis

Clearance of Apoptotic Cells11. Apoptotic Cell Clearance and its ImplicationsProf. Peter Henson – National Jewish Medical Research Center, University ofColorado Health Sciences Center, USAUptake of apoptotic cells – Specialized forms of phagocytosis – Efferocytosis – Anti-inflammatory and anti-immunogenic responses to apoptotic cells – Tissue cell deletionand replacement – Tissue homeostasis – Autoimmunity, fibrosis and emphysema

12. Degradation of Apoptotic CellsProf. Shigekazu Nagata – Osaka University Medical School, JapanDNA fragmentation during apoptosis – DNA degradation in macrophages –Activation of innate immunity by undigested DNA – Engulfment of apoptotic cells– Phosphatidylserine-dependent engulfment of apoptotic cells – Autoimmunedisease caused by unengulfed apoptotic cells

13. Signaling During Engulfment: The Beginningsof a Good MealProf. Kodi Ravichandran – Carter Immunology Center, University of Virginia, USABackground on engulfment of apoptotic cells – Early lessons from the worm andgraduating to mammals – GULP and LRP1 in engulfment – Role of ELMO andDock180 proteins in engulfment – The mechanisms leading to Rac activation andregulation of the cytoskeleton during engulfment



ApoptosisFundamentals, Pathways, Clinical Applications and Role in Disease



Non-Apoptotic Cell Death Programs

14. Lysosomal Cell Death Pathways: NewPossibilities for Cancer TherapyProf. Marja Jäättelä – Institute of Cancer Biology, Danish Cancer Society, DenmarkCell death in cancer – Lysosomes and lysosomal cell death – Lysosomal changesin cancer – Siramesine, a drug that targets lysosomes and kills cancer cells in vitroand in vivo

15. Autophagic Cell DeathDr. Eric Baehrecke – Center for Biosystems Research, University of MarylandBiotechnology Institute, USAMorphological forms of cell death – What is autophagy and why is it of interest tocell death researchers? – Discovery of autophagy genes – How is autophagyregulated? – Class I PI3K signaling and Class III PI3K signaling – Ubiquitin-likeconjugation systems – Where has autophagic cell death been observed? – What arethe possible roles of autophagy in dying cells? – Evidence in support of autophagyprolonging cell survival – Studies in flies and mammals suggest that both autophagyand caspases can be involved in cell death of the same cell – Evidence in support ofautophagy promoting cell death – Inhibition of caspase-8 promotes autophagic celldeath of L929 cells by autophagic degradation of catalase

Apoptosis and Disease

16. p53 and ApoptosisProf. Moshe Oren – The Weizmann Institute of Science, Israelp53 as a tumor suppressor – Regulation of transcription by p53 – Activation ofp53 by oncogenic stress – Transcriptional and non-transcriptional mechanisms forp53-mediated apoptosis – Regulation of p53 by Mdm2 – Evolutionaryconservation of p53 function – Mutant p53 gain of function – p53-based cancertherapy

17. The p53 Family: Function and MolecularMechanismsProf. Gerry Melino – University of Rome “Tor Vergata”, Italy, and MRCToxicology Unit, University of Leicester, UK The p53/p63/p73 family – DNA damage elicits repair mechanisms involving thetumour suppressor gene p53 and the two newer members of the same family: p63and p73 – The molecular events driven by DNA damage to elicit the function ofp63/p73 and their transcriptional regulation – The biological effect of p63/p73in the immune and neural systems

18. Apoptosis in the Immune SystemProf. Peter Krammer – German Cancer Research Center, Germany Basics of apoptosis – Signaling through death receptors – Apoptosis in theimmune system – Apoptosis in diseases: sepsis, stroke and spinal cord injury –Apoptosis and killer T cells – Apoptosis and p53 – Apoptosis and cancer

19. Apoptosis in the Nervous SystemProf. Pierluigi Nicotera – MRC Toxicology Unit, University of Leicester, UK Cell death programs in the nervous system – Programmed cell death (PCD) –Similarities and differences in the classical PCD paradigm between worms andvertebrates – Conserved death mechanisms – Apoptosis, necrosis and autophagiccell death – Other death subroutines – The caspases – Intracellular ATP level –Common characteristics of cell death programmes in vertebrates – Differentexecutioners and cell death routines – Brain ischemia – Calpain activation –Spatial control of cell death – Spatial control of neurodegeneration – BoNT/C –Mitochondrial dysfunction – Spatial control of cell death in central neurons

20. Apoptosis and Disease: Apoptotic CellClearance DeficienciesProf. Martin Herrmann – Institute for Clinical Immunology, University ofErlangen-Nürnberg, Germany Anti-inflammatory and immunosuppressive effects of apoptotic cells –Autoimmune disease and clearance of dying cells – Clearance deficiency ofapoptotic cells – Germinal centre tingible body macrophage deficiency – Modelfor the generation of nuclear autoimmunity – Annexin V as adjuvans forirradiated tumor cells

Clinical Application of Apoptosis Research

21. Endothelial Cell Apoptosis Regulates Normaland Tumor Tissue Damage During RadiotherapyProf. Richard Kolesnick – Memorial Sloan-Kettering Cancer Center, USAEndothelial apoptosis – Role in tumor response to radiation therapy – Tissuedamage results from depletion of stem cells and cells with clonogenic capacity –Radiation targets the DNA leading to reproductive (mitosis-associated) or apoptoticcell death – Modifications of DNA damage recognition and repair pathwaysdetermine the level of tissue sensitivity to radiation – Sphingomyelin – Ceramide –GI tract and bone marrow: very radiation responsive – Growth patterns of tumors– The two-target model for single-dose radiotherapy of experimental tumors –Engaging the vascular component of tumor response to radiation

22. Caspase Inhibitors in Drug DiscoveryDr. Tom O’Brien – Genentech, USA Apoptotic caspases – Inflammatory caspases – Validation of caspase involvementin disease – Animal models – Rheumatoid arthritis – Liver degeneration – Smallmolecule drug discovery – Inhibitor specificity – Reversible and irreversiblebinding inhibitors – Clinical trial data

23. Targeting Apoptosis Pathways in CancerTherapy: From Molecules to TherapeuticsDr. Simone Fulda – University Children’s Hospital Ulm, GermanyApoptosis in cancer – Apoptosis signaling pathways – Death receptor pathway –Mitochondrial pathway – Targeting the death receptor pathway – Bcl-2 familyproteins: structure and function – Targeting Bcl-2 family proteins – IAPs: structureand function – Targeting IAPs

24. Therapeutic Options for Cancer Therapy:Targeting the Apoptosis PathwaysDr. Irene Ghobrial – Dana-Farber Cancer Institute, USA Apoptosis pathways – Regulation of the intrinsic and extrinsic pathways – Noveltherapeutic agents in cancer therapy that target the apoptosis pathways and themodulators of apoptosis

ApoptosisFundamentals, Pathways, Clinical Applications and Role in Disease

Supporting Partners:

Speaker BiographiesDr. Eric Baehrecke – Center for Biosystems Research, University ofMaryland Biotechnology Institute, USAEric Baehrecke is an Associate Professor at the University of MarylandBiotechnology Institute. He obtained his PhD from the University ofWisconsin, Madison, where he studied polyembryonic development.Current research is focused on the relationship between autophagy,caspases and other degradation mechanisms in the survival and deathof cells during normal and abnormal development.

Dr. Simone Fulda – University Children’s Hospital Ulm, GermanySimone Fulda studied medicine at the University of Cologne, as well asin Boston, San Francisco, Phoenix and Dublin between 1988 and1995. She trained as a molecular and cell biologist and pediatriconcologist in Germany and America. Her research focuses onunderstanding apoptosis signaling pathways activated by anti-cancertherapies and on developing novel apoptosis targeted experimentalstrategies for cancer therapy.

Dr. Irene Ghobrial – Dana-Farber Cancer Institute, USAIrene Ghobrial is a consultant for Waldenstrom Macroglobulinemia atthe Dana-Farber Cancer Institute. Dr. Ghobrial’s research focuses onunderstanding the regulation of homing and migration inWaldenstrom Macroglobulinemia (WM) and Multiple Myeloma (MM),and on identifying dysregulated signaling proteins that can bespecifically targeted with novel therapeutic agents, specifically focusingon the role of the PI3K and PKC pathways in WM and MM.

Prof. Douglas Green - St. Jude Children's Research Hospital, USADouglas Green is an Adjunct Professor of Biology in the Division ofCellular Immunology at the La Jolla Institute for Allergy andImmunology, USA. He received his PhD from Yale University. Hislaboratory studies the process of apoptosis, or active cell death, andhow it functions in the regulation of the immune system. His researchextends from the role of apoptosis in the regulation of immuneresponses in the whole organism, to the fundamental molecular eventsdirecting the death of the cell.

Prof. Michael Hengartner – Institute of Molecular Biology, Universityof Zurich, SwitzerlandMichael Hengartner is the Ernst Hadorn Professor of Molecular Biologyat the Institute of Molecular Biology, University of Zurich in Switzerland.The Hengartner lab uses the nematode C. elegans as a modelorganism to understand basic biological processes. His current workfocuses on the molecular pathways that control apoptosis duringdevelopment and in response to genotoxic stress and on the removalof apoptotic cells by their neighbours.

Prof. Peter Henson – National Jewish Medical Research Center,University of Colorado Health Sciences Center, USAPeter Henson is an immunopathologist whose main interests have beenin the study of inflammation and more recently in apoptosis as one ofthe mechanisms for its resolution. This led to the recognition thatapoptotic cells, including inflammatory cells, are deleted frommetazoan tissues as a result of being phagocytosed by bothprofessional and non-professional phagocytes. Dr. Henson received hisPhD from the University of Cambridge and he has been at the NationalJewish Medical Research Center for the last 30 years.

Prof. Martin Herrmann – Institute for Clinical Immunology, Universityof Erlangen-Nürnberg, GermanyMartin Herrmann is a Professor of Experimental Medicine. He is anationally and internationally recognized rheumatologist whose mainresearch has been on the immunogenicity of dying cells and onautoimmunity. Dr. Herrmann is Group Leader of the autoimmuneresearch laboratory of the Department for Internal Medicine 3 at theUniversity of Erlangen-Nürnberg.

Dr. David Huang – Walter and Eliza Hall Institute of MedicalResearch, AustraliaDavid Huang is a Senior Research Fellow at the Walter and Eliza HallInstitute of Medical Research, Australia. He graduated in medicinefrom the University of London and subsequently undertook specialtytraining in internal medicine and in haematology. He joined the HallInstitute in 1994 as a post-doctoral fellow and is currently one of thelaboratory heads in the Molecular Genetics of Cancer Division there.The major research interests of his laboratory are the molecularmechanisms that regulate cell death (apoptosis) and cell survival inmammalian cells and understanding how de-regulation of the celldeath machinery can lead to cancer.

Prof. Marja Jäättelä – Institute of Cancer Biology, Danish CancerSociety, DenmarkMarja Jäättelä is a Professor of Tumor Biology at the University ofCopenhagen and Head of the Apoptosis Department at the Institute ofCancer Biology, Danish Cancer Society. Her current research focuseson exploring the cancer-associated changes in lysosomal composition,trafficking and function in order to develop novel anti-cancer drugstargeting cancer cell lysosomes.

Prof. Richard Kolesnick – Memorial Sloan-Kettering Cancer Center,USARichard Kolesnick is a Professor in the Laboratory of SignalTransduction at the Memorial Sloan-Kettering Cancer Center, NewYork. He is an authority on cell signaling and he has played a principalrole in the discovery of the “sphingomyelin signal transductionpathway”, which appears to be crucial in the induction of apoptosis.

Prof. Peter Krammer – German Cancer Research Center, GermanyPeter H. Krammer is a Professor of Medicine and nationally andinternationally recognized in his main field of research, apoptosis. Dr.Krammer is Director of the Tumor-Immunology Program of the GermanCancer Research Center in Heidelberg, Germany, where he is Head ofthe Division of Immunogenetics investigating growth of normal andmalignant lymphocytes.

Prof. Yuri Lazebnik – Cold Spring Harbor Laboratory, USAYuri Lazebnik is a Professor at Cold Spring Harbor Laboratory. Hereceived his PhD from St. Petersburg State University in 1986. Hislaboratory seeks to understand how cells become cancerous, howcancer cells evolve and how they can be killed selectively. Dr. Lazebnikis an internationally recognized expert on mechanisms of cell death andthe role of caspases in this process. His research on apoptosis has beenmotivated by his interest in the origin, fate and viability of cancer cells.

Prof. Jean-Claude Martinou – University of Geneva, SwitzerlandJean-Claude Martinou is Professor and Director of the Cell BiologyDepartment at the University of Geneva. He leads a research teaminternationally recognized for its work on the role of mitochondria inapoptosis and on the role of the process of mitochondrial fusion andfission in cell homeostasis.



Speaker Biographies



Prof. Gerry Melino – University of Rome “Tor Vergata”, Italy, andMRC Toxicology Unit, University of Leicester, UKGerry Melino currently works as Programme Leader for the MedicalResearch Council Toxicology Unit in Leicester, UK. He is also FullProfessor of Molecular Biology at the University of Rome “Tor Vergata”in Italy. He obtained his PhD in 1984 at the University of London in theChemical Pathology Department. Professor Melino has acted asconsultant and scientific advisor for companies as well as governmentinstitutions. He also has significant editorial activity as Founder andEditor-in-Chief of the journal Cell Death and Differentiation. Hisscientific interest is focused on programmed cell death.

Prof. Shigekazu Nagata – Osaka University Medical School, JapanShigekazu Nagata is a Professor of Genetics. He was educated as abiochemist at the University of Tokyo. He joined the Osaka BioscienceInstitute as Head of the Molecular Biology Department in 1987. There,he started to work on the Fas and Fas ligand system, which led him topropose “a death factor and its receptor”. Since 1995, Dr. Nagata hasbeen a Professor in the Department of Genetics at Osaka UniversityMedical School. He is an editorial board member of Immunity, CellDeath and Differentiation and International Immunology.

Prof. Pierluigi Nicotera – MRC Toxicology Unit, University of Leicester,UKPierluigi Nicotera is the Director of the Medical Research CouncilToxicology Unit at the University of Leicester. He received his PhD inbiochemical toxicology from the Karolinska Institute. He is aneditorial board member of the journals Neuron, Cell Death andDifferentiation, Chemical Research in Toxicology and MolecularNeurobiology. The major research focus of his scientific career hasbeen to understand fundamental mechanisms regulating cell deathand survival.

Dr. Tom O’Brien – Genentech, USATom O’Brien is a member of the small molecule discovery group atGenentech. Prior to this he was a Senior Scientist at SunesisPharmaceuticals. Dr. O’Brien’s research has focused on identifyingsmall molecule inhibitors that display specificity for different caspasefamily members. Additionally, he has played a pivotal role indeveloping novel technologies that aid the identification andadvancement of small molecule leads against a number of importanttherapeutic targets.

Prof. Moshe Oren – The Weizmann Institute of Science, IsraelMoshe Oren is a cancer molecular biologist in the Department ofMolecular Cell Biology at the Weizmann Institute of Science. His mainresearch focuses on the p53 tumor suppressor and its relationship tocancer. The research conducted by Prof. Oren has led to the cloning ofthe p53 gene, the identification of p53 as a tumor suppressor and theelucidation of its crucial role as a regulator of apoptosis.

Prof. Kodi Ravichandran – Carter Immunology Center, University ofVirginia, USAKodi S. Ravichandran is a Professor of Microbiology. He is a nationallyand internationally recognized immunologist whose main research hasbeen on the molecular understanding of signaling during engulfmentof apoptotic cells and the signals regulating the function of cells of theimmune system. Dr. Ravichandran is one of the leaders in the field of

engulfment of apoptotic cells and his work on the identification andcharacterization of specific players involved in clearing corpses inmammals has begun to provide the molecular understanding of thisfundamentally important biological process.

Prof. Guy Salvesen – The Burnham Institute for Medical Research,USAGuy Salvesen earned his PhD in biochemistry from CambridgeUniversity in 1980. He is an internationally recognized expert in thebiochemistry of proteolytic signaling, with a special emphasis onprogrammed cell death. Dr. Salvesen is Director of the Program onApoptosis and Cell Death Research and Director of Scientific Trainingat the Burnham Institute for Medical Research. Dr. Salvesen holds anadjunct appointment as Professor of Pathology at the University ofCalifornia, San Diego. His research interests are primarily focused onthe development of technologies to aid in the understanding of howcancer and degenerative diseases arise from previously healthy cells.

Prof. Yigong Shi – Princeton University, USAYigong Shi is a Professor in the Department of Molecular Biology atPrinceton University. He received his PhD in biophysics at JohnsHopkins University School of Medicine in 1995. He joined the facultyat Princeton University in 1998 and was made Full Professor in2003. Dr. Shi’s research is aimed at understanding the molecularmechanisms involved in oncogenesis. His approaches encompass avariety of biochemical and biophysical methods, particularly X-raycrystallography.

Dr. Richard Siegel – NIAMS, National Institutes of Health, USARichard Siegel obtained his MD, PhD and clinical training in internalmedicine and rheumatology at the University of Pennsylvania. In2001, Dr. Siegel moved to the National Institute of Arthritis,Musculoskeletal Diseases and Skin at the NIH as a PrincipalInvestigator. His current research interests include regulation ofcellular survival and death in the immune system by TNF receptorand other signaling pathways, and the relevance of these pathwaysto autoimmune diseases and immune tolerance.

Prof. Herman Steller – Howard Hughes Medical Institute, TheRockefeller University, USAHerman Steller is Strang Professor and Head of the Laboratory ofApoptosis and Cancer Biology at the Rockefeller University. He is alsoa Howard Hughes Medical Investigator. Prior to this he was Professorof Neurobiology at MIT. He is interested in the mechanism by whichcells undergo programmed cell death, how this process is regulatedby distinct signaling pathways and how abnormal regulation ofapoptosis contributes to a variety of diseases, including cancer.

Prof. Henning Walczak – German Cancer Research Center,GermanyHenning Walczak is the Head of the Apoptosis Regulation ResearchGroup at the Tumor-Immunology Program of the German CancerResearch Center in Heidelberg. He is an internationally recognizedresearcher in the apoptosis field with a special focus on thebiochemistry of the death receptor-mediated pathway. The aim of theresearch conducted in his lab is to identify the molecular mechanismsthat allow for specific killing of tumor cells by members of the TNFligand family and ultimately how to apply them clinically.

Speaker Biographies

ApoptosisFundamentals, Pathways, Clinical Applications and Role in DiseaseView sample talks and order online at www.hstalks.com/apoptosis/ or fill in the form belowFor further information please contact an Account Manager on +44 (0) 8702 360 361 or email [email protected] are compatible with PC WIN98+ and Mac OSX+

1. Licence1.1 For purchasers of an Single User License: Subject to the following terms and conditions, Henry Stewart Talks Ltd (“HST”) grants to the licensee (the “Licensee”)

a non-exclusive, non-transferable, revocable license for one named individual to view and listen to the contents of this CD-ROM (the “Materials”) on not morethan one computer at any one time.

1.2 For purchasers of a Research Group License: Subject to the following terms and conditions, Henry Stewart Talks Ltd (“HST”) grants to the licensee (the“Licensee”) a non-exclusive, non-transferable, revocable license for members of one research group located in the same institution and country, managed bya single named principal investigator to view and listen to the contents of this CD-ROM (the “Materials”) on not more than ten computers at any one time.

1.3 For purchasers of a Site License: Subject to the following terms and conditions, Henry Stewart Talks Ltd (“HST”) grants to the licensee (the “Licensee”) a non-exclusive, non-transferable, revocable license to use this CD-ROM and its contents (the “Materials”) in accordance with the provisions set out in Clause 6 below.

1.4 Online access: All persons entitled to use the CD-ROM and its contents shall have the right to view and listen to the materials via online access to one or moreHST servers in accordance with HST’s then current terms and conditions for online access (Regulations). HST shall give Licensees at least three months noticeof changes to its Regulations.

2. Unauthorized Use of MaterialsExcept as provided in Clause 6 below, the Licensee agrees not to copy, dissemble, alter, amend, adapt, distribute or in any way duplicate the Materials, give possessionof the Materials to any third party, remove or alter any logo, symbols, labels, copyright or other notice included in the Materials, or sell or in any way make commercialgain from the Materials.

3. Intellectual PropertyThe Licensee acknowledges HST’s ownership of the Materials, and that all copyright and other intellectual property in the Materials will remain in the exclusiveownership of HST.

4. No WarrantiesThe Materials are provided to the Licensee on an “as is” basis and HST makes no warranty or representation about the completeness, accuracy, satisfactory quality,merchantability, and/or the fitness of the same for any purpose and the Licensee acknowledges that the Materials are not necessarily error-free.

5 Limitation of LiabilitySubject to Clause 5.2 below:

5.1.1 except for any refund of any amount paid by the Licensee for the materials or the replacement of the Materials by HST where the Licensee is unable to accessthe Materials because of a physical defect with the CD-ROM or an error in the printing or coding of the CD-ROM, HST shall have no liability to the Licenseefor any damages, loss, expense, claim or award directly or indirectly incurred or suffered by the Licensee, in tort contract or otherwise to any extent whatsoeverincluding, without limitation, for lost profits, data or information of any kind or for consequential, special, indirect, incidental, punitive or other damages;

5.1.2 HST disclaims all liability with respect to the Materials either express or implied including, but without limitation, any liability for any UnacceptableContent appearing in or forming part of the Materials. For these purposes “Unacceptable Content” means anything appearing on, incorporated in orassociated with the Materials which: (i) is defamatory, obscene, in contempt of court or in contravention of any law or statute or infringes the rights,including the intellectual property rights, of any third party; or (ii) promotes violence or discrimination or illegal activities; or (iii) contains any viruses,worms, trojan horses or any other contaminants that may be used to access and/or modify, delete or damage any data files of other computer programs.

5.2 HST does not exclude any liability for breach of any condition implied under section 12 of the Sale of Goods Act 1979 or section 2 or the Supply of Goods andServices Act 1982 or for fraudulent misrepresentation.

5.3 If any exclusion contained in these terms is held to be invalid for any reason and HST becomes liable for loss or damage that may lawfully be limited such liabilityshall be limited to the commercial value of the Materials at the date hereof.

6. Distribution Rights6.1 Where the Materials are provided for use by a bona fide not for profit academic institution, the Licensee shall be permitted to:

6.1.1 provide access to the Materials to any and all employees and students of the Licensee employed or enrolled in one designated country (together “theMembers”);

6.1.2 place copies of the Materials on one or more servers with access available online (whether on-site or remote) by the Members; and6.1.3 make and supply copies of the CD-ROM to any of the Members on the same terms and subject to the same conditions as set out in these Terms and

Conditions of Use and in particular the provisions in Clause 2 above.6.2 Where the Materials are provided for use by a commercial or other non bona fide academic not for profit organization, the Licensee shall be permitted to:

6.2.1 provide access to the Materials to any and all employees of the Licensee employed by the organization at one geographically contiguous location(together “the Members”);

6.2.2 place copies of the Materials on one or more servers with access available online by the Members; and6.2.3 make and supply copies of the CD-ROM to any of the Members on the same terms and subject to the same conditions as set out in these Terms and

Conditions of Use and in particular the provisions in Clause 2 above.

7. Governing LawThis Agreement will be governed by and interpreted in accordance with English Law.

Henry Stewart Talks Ltd., Russell House, 28-30 Little Russell Street, London WC1A 2HN. Registration Number: 4833828

1. Purchase Costs – Please tick appropriate rate

Rate for Academic Institutions iv Rate for Commercial InstitutionsSingle User Research Group Site License*** Single User Research Group Site License***

License* License** License* License**UK (excl. VAT) £350 £480 £980 £350 £990 £1,510UK i (Total Price inc. VAT @ 17.5%) □ £411.25 □ £564 □ £1,151.50 □ £411.25 □ £1,163.25 □ £1,774.25Other EU Countries ii □ €530 □ €730 □ €1,490 □ €530 □ €1,495 □ €2,290N. America & Rest of the World iii □ $690 □ $945 □ $1,930 □ $690 □ $1,950 □ $2,969Number of Users Permitted Single User Up to 10 computers Unlimited Single User Up to 10 computers Unlimited

i UK Customers: UK customers will be charged in Sterling and must pay price inclusive of VAT. ii Other EU Customers: Other EU customers are entitled to purchase exclusive of VAT if a local VAT number is provided. Local VAT number ____________________________________________________________

□ I do not have a VAT number and will pay the above price plus VAT at 17.5% iii N. American and Rest of the World customers: N. American and Rest of the World customers will be charged at the US Dollar rate and are not required to pay VAT or sales tax on the purchase.iv Academic Rate: The discounted rate is available to educational establishments and individuals employed by them.

* Single User License: Series are provided to customers on CD-ROM for use by a single user on one computer.** Research Group License: Series are provided to customers on CD-ROM and may be installed on up to 10 computers accessed by members of the same research group located in one designated country.*** Site License: Hosted online streaming access is provided via Henry Stewart Talks designated servers with access controlled by IP verification. For easy offline access, a copy of the series is also provided on CD-ROM.

Subject to the full terms and conditions of use, the one time payment license permits unlimited access to all members of a purchasing organization usually located in one designated country.

2. Method of Payment Payment can be made by either cheque or credit card. Please indicate your preferred payment option:□ I enclose a cheque payable to Henry Stewart Talks Ltd □ Please send me an invoice containing full payment instructions. □ I wish to pay by credit card.

Card Number □□□□□□□□□□□□□□□□ Expiry Date ______/______

Signature of Cardholder ____________________________________________________________ CVC Number (last 3 digits on the reverse of your card) ___ ___ ___ Please attach cardholder’s name/address should it differ from that given belowPlease note that series will be disptached only on receipt of full payment or a signed purchase order approved by Henry Stewart Talks.

3. Purchaser Details

Title First Name Last Name

Position Organization

Address

Postcode/Zip

Country Telephone

E-mail Fax

Signature Date

Please tick box if you do not wish to receive information on: Henry Stewart Talks Series □ Henry Stewart Conferences and Publications □ Other products from selected media partners □

4. Delivery/Billing Address – please complete below, or attach if different to the above purchaser details

5. Send to

HST, Russell House, 28/30 Little Russell Street, London WC1A 2HN, UK +44 (0) 8702 360 361 +44 (0)20 7404 2081 [email protected]

6. Terms & Conditions n Please tick here to confirm that you have read and understood and agree to be bound by the terms and conditions below.

HST24

Please charge my □ Amex □ Visa □ Mastercard

Our ref: Please quote this reference when booking via the Internet or by phone

AA BB CC DD EE FF GG HH I I JJ KK LL MM

a henry stewart talks series in biomedicine and the life ... documents/apoptosis brochure for...

Documents